

Localization of Cyclopropane Modifications in Bacterial Lipids via 213 nm Ultraviolet Photodissociation Mass Spectrometry

Molly S. Blevins, Dustin R. Klein, and Jennifer S. Brodbelt*


Department of Chemistry, University of Texas at Austin, Austin, TX 78712, United States

*Corresponding author: jbroadbelt@cm.utexas.edu

Supporting Information



Table of Contents

Content	Page no.
1. Possible fragmentation pathway for UVPD of cyclopropane rings in bacterial lipids	S-2
2. <i>In vivo</i> generation of bacterial cyclopropane glycerophospholipid from double bond precursor	S-3
3. Structures of all cyclopropane lipid standards	S-4
4. MS1 spectra of PE (16:0/17:1(c9Z)) and PC (16:0/17:1(c9Z)) with corresponding structures	S-5
5. Calibration curve for PE (16:0/17:1(c9Z)) cyclopropane diagnostic ion LC/UVPD-MS peak areas as a function of injection amount	S-6
6. HCD spectrum of α -MA (C-80(c16Z, c32Z)) with fragment ion map	S-7
7. Comparison of 193 and 213 nm UVPD for cyclopropane localization in PE (16:0/17:1(c9Z))	S-8
8. HCD and UVPD spectra of methoxy-MA of <i>m/z</i> 1224 with corresponding fragment ion maps	S-9
9. LC-MS base peak chromatogram of <i>Mtb</i> H37rV lipid extract	S-10
10. LC-MS base peak chromatograms of <i>Mtb</i> HN878 and CDC1551 lipid extracts with corresponding lists of identified MAs	S-11




Scheme S1. Possible fragmentation pathway for UVPD of cyclopropane rings in bacterial lipids with example shown for PE (16:0/17:1(c9Z)). Boxed products will be detected via MS as depicted product ions retains the phospholipid headgroup, differing by CH_2 and accounting for an observed mass difference of 14 Da

PE (16:0/16:1(9Z))




S-adenosylmethionine



Cyclopropane
Synthase

PE (16:0/17:1(c9Z))



Scheme S2. *In vivo* generation of bacterial cyclopropane glycerophospholipid from double bond precursor via *S*-adenosylmethionine methylene addition and cyclopropane synthase catalysis (PDB entry 6BQC)

Lipid Name	Lipid Structure	Exact Mass (Da)
(2R)-3-(((2-aminoethoxy)(hydroxy)phosphoryl)oxy)-2-((8-((1S,2R)-2-hexylcyclopropyl)octanoyl)oxy)propyl palmitate PE (16:0/17:1(c9Z))		703.515
2-((((R)-2-((8-((1S,2R)-2-hexylcyclopropyl)octanoyl)oxy)-3-(palmitoyloxy)propoxy)(hydroxy)phosphoryl)oxy)-N,N,N-trimethylethan-1-aminium PC (16:0/17:1(c9Z))		746.569
(2R)-2-((1R)-1-hydroxy-14-(2-(14-(2-octadecylcyclopropyl)tetradecyl)cyclopropyl)tetradecyl)hexacosanoic acid compound with dihydrogen (1:24) α-mycolic acid (C-80(c16Z, c32Z))		1137.174

Table S1. Structures of all cyclopropane lipid standards




Figure S2. Calibration curve for PE (16:0/17:1(c9Z)) based on detection of diagnostic ions (m/z 590 and 604) from negative ion mode 213 nm LC/UVPD-MS enabling determination of LOD as 45 pmol. Calibration curve was generated based on linear regression analysis of peak areas with seven-point boxcar smoothing over the range of 20 to 200 pmol with S/N=3 and LOD experiments were performed using an activation period of 100 msec (corresponding to 250 pulses) and performed in triplicate as indicated by error bars included on the graph. For this LOD measurement, the UVPD efficiency of caffeine used to calibrate and optimize UVPD performance was measured as 25% using 125 laser pulses (50 ms activation period).

α -mycolic acid (C-80(c16Z, c32Z))
 m/z 1164.20





Figure S3. Negative mode HCD spectrum of α -mycolic acid (C-80(c16Z, c32Z)) with corresponding fragment ion map.



b)

Wavelength (nm)	213	193
Activation parameters	500 pulses 1.5 uJ per pulse 200 ms activation period	10 pulses 5 mJ per pulse 20 ms activation period
Abundance of precursor prior to UVPD (m/z 702.5)	111,093,064	29,162,016
Summed abundances of diagnostic ions (m/z 590 and 604)	167,758	318,411
Fragmentation efficiency (%) (fragment abundance/precursor abundance)	0.2	1.1

Figure S4. a) Comparison of negative mode 193 and 213 nm UVPD spectra of PE (16:0/17:1(c9Z)) of precursor m/z 702 with cyclopropane diagnostic ions of m/z 590 and m/z 604 labelled in bold font. The 100X magnification applies to both spectra. **b)** Summary of 193 and 213 nm UVPD parameters along with fragment-to-precursor ratio showing higher efficiency of 193 nm UVPD compared to 213 nm UVPD. For each type of UVPD, the laser is unfocused.




Figure S5. **a)** HCD and **b)** 213 nm UVPD spectra of methoxy-mycolic acid of m/z 1224 in negative ion mode and corresponding structural identifications with fragment maps: **c)** methoxy-mycolic acid (C-83(c18 Δ)) and **d)** methoxy-mycolic acid (C-83(c20 Δ)).





Figure S6. Negative mode LC-MS base peak chromatogram of *Mtb* H37rV lipid extract.



c)

m/z [M-H] ⁻	Chemical Formula	MA Class	m/z R ₂ (α branch)	C _{19:0} stat		Ring position	C _{19:0} stat		
				m/z diagnostic ions			m/z diagnostic ions		Ring position
1108.1515	C ₇₈ H ₁₄₀ O ₃	alpha	367, 395	563.5511	577.5593	c12Δ (395), c14Δ (367)	799.8073 813.8130	813.8130 827.8345	c28Δ (395), c30Δ (367) c29Δ (395), c31Δ (367)
1136.1825	C ₇₈ H ₁₃₂ O ₃	alpha	367, 395	591.5862	605.5973	c14Δ (395), c16Δ (367)	827.8345 827.8371	841.8480 841.8550	c30Δ (395), c32Δ (367) c30Δ (395), c32Δ (367)
1164.2151	C ₈₀ H ₁₅₀ O ₃	alpha	367, 395	619.6111	633.6366	c16Δ (395), c18Δ (367)	841.8550 855.8824	855.8824 869.8666	c31Δ (395), c33Δ (367) c32Δ (395), c34Δ (367)
1224.2725	C ₈₀ H ₁₆₀ O ₄	methoxy	367, 395	647.6436	661.6670	c18Δ (395), c20Δ (367)	-	-	-
1252.3030	C ₈₀ H ₁₆₀ O ₄	methoxy	395	675.6806	689.7073	c20Δ	-	-	-
1278.3196	C ₈₀ H ₁₇₀ O ₄	keto	395	661.6498	675.6744	c19Δ	-	-	-
1280.3351	C ₈₇ H ₁₇₂ O ₄	methoxy	395	675.6864 689.7028	689.7028 703.6973	c20Δ c21Δ	-	-	-
1294.3502	C ₈₈ H ₁₇₄ O ₄	methoxy	395	703.6973 661.6572	717.7114 675.6744	c22Δ c19Δ	-	-	-

d)

m/z [M-H] ⁻	Chemical Formula	MA Class	m/z R ₂ (α branch)	C _{19:0} stat		Ring position	C _{19:0} stat		
				m/z diagnostic ions			m/z diagnostic ions		Ring position
1108.1520	C ₇₈ H ₁₄₀ O ₃	alpha	339, 367, 395	563.5494	577.5612	c12Δ (395), c14Δ (367), c16Δ (339)	799.8046 813.8129	813.8129 827.8302	c28Δ (395), c30Δ (367), c32Δ (339) c29Δ (395), c31Δ (367), c33Δ (339)
1136.1833	C ₇₈ H ₁₃₂ O ₃	alpha	367, 395	591.5839	605.6035	c14Δ (395), c16Δ (367)	827.8302 827.8284	841.8393 841.8535	c30Δ (395), c32Δ (367), c34Δ (339) c30Δ (395), c32Δ (367)
1164.2148	C ₈₀ H ₁₅₀ O ₃	alpha	367, 395	619.6184	633.6296	c16Δ (395), c18Δ (367)	841.8535 855.8654	855.8617 869.8852	c31Δ (395), c33Δ (367) c30Δ (395), c32Δ (367)
1224.2728	C ₈₀ H ₁₆₀ O ₃	methoxy	367, 395	647.6470	661.6630	c18Δ (395), c20Δ (367)	-	-	-
1252.3030	C ₈₀ H ₁₆₀ O ₄	methoxy	367, 395	661.6651 675.6806	675.6806 689.6962	c19Δ (395), c21Δ (367) c20Δ (395), c22Δ (367)	-	-	-
1280.3350	C ₈₇ H ₁₇₂ O ₄	methoxy	367, 395	675.6934 689.6998	689.6998 703.7048	c20Δ (395), c22Δ (367) c21Δ (395), c23Δ (367)	-	-	-
1294.3500	C ₈₈ H ₁₇₄ O ₄	methoxy	367, 395	703.7048 661.6513	717.7048 675.6749	c22Δ (395), c24Δ (367) c19Δ (395), c21Δ (367)	-	-	-
1308.3669	C ₈₈ H ₁₇₆ O ₄	methoxy	395	703.7062	717.7184	c22Δ	-	-	-
1322.3833	C ₉₀ H ₁₇₄ O ₄	methoxy	367, 395	689.6821	703.7161	c21Δ (395), c23Δ (367)	-	-	-

Figure S7. Negative mode LC-MS base peak chromatogram for **a)** *Mtb* HN878 lipid extract and **b)** *Mtb* CDC1551 lipid extract, and list of identified mycolic acids from LC-MS/MS for **c)** *Mtb* HN878 lipid extract and **d)** *Mtb* CDC1551 lipid extract.